A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Clinical trial NCT02302339 · TERMINATED
Trial details
- NCT number
- NCT02302339
- Sponsor
- Celldex Therapeutics
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-01
- Primary completion
- 2018-06-14
- Enrollment
- 132
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.